CR20200652A - Compuestos que aumentan la actividad del proteosoma - Google Patents

Compuestos que aumentan la actividad del proteosoma

Info

Publication number
CR20200652A
CR20200652A CR20200652A CR20200652A CR20200652A CR 20200652 A CR20200652 A CR 20200652A CR 20200652 A CR20200652 A CR 20200652A CR 20200652 A CR20200652 A CR 20200652A CR 20200652 A CR20200652 A CR 20200652A
Authority
CR
Costa Rica
Prior art keywords
proteasome activity
activity enhancing
enhancing compounds
compounds
towards
Prior art date
Application number
CR20200652A
Other languages
English (en)
Inventor
Benito Munoz
Matthew Cullen
Cecilia M Bastos
Daniel Parks
Original Assignee
Proteostasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteostasis Therapeutics Inc filed Critical Proteostasis Therapeutics Inc
Publication of CR20200652A publication Critical patent/CR20200652A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Abstract

<p>La presente invención se dirige hacia compuestos que tienen la Fórmula (Ib) o las Fórmulas (III) y las sales, solvatos y clatratos de estos farmacéuticamente aceptables, composiciones de estos, así como también hacia el uso de dichos compuestos en los métodos para el tratamiento de una afección asociada con una disfunción en la proteostasis.</p>
CR20200652A 2018-06-27 2019-06-27 Compuestos que aumentan la actividad del proteosoma CR20200652A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690563P 2018-06-27 2018-06-27
US201862690565P 2018-06-27 2018-06-27
PCT/US2019/039600 WO2020006296A1 (en) 2018-06-27 2019-06-27 Proteasome activity enhancing compounds

Publications (1)

Publication Number Publication Date
CR20200652A true CR20200652A (es) 2021-04-28

Family

ID=67439356

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200652A CR20200652A (es) 2018-06-27 2019-06-27 Compuestos que aumentan la actividad del proteosoma

Country Status (17)

Country Link
US (2) US11560385B2 (es)
EP (1) EP3814338A1 (es)
JP (1) JP2021529792A (es)
KR (1) KR20210024588A (es)
CN (1) CN112585132A (es)
AU (1) AU2019295765A1 (es)
BR (2) BR122023023216A2 (es)
CA (1) CA3103954A1 (es)
CL (1) CL2020003380A1 (es)
CR (1) CR20200652A (es)
IL (1) IL279698A (es)
MA (1) MA53014A (es)
MX (1) MX2020014082A (es)
PE (1) PE20211804A1 (es)
PH (1) PH12020552261A1 (es)
SG (1) SG11202013026WA (es)
WO (1) WO2020006296A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3104654A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
CN111423353B (zh) * 2020-04-29 2022-03-22 湖北省生物农药工程研究中心 多取代n-芳基吡咯类化合物及其制备方法
CN112142642B (zh) * 2020-10-15 2022-03-04 华侨大学 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法
WO2023107597A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Bicyclic heteroaromatic amide compounds and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1142508A (en) 1966-04-27 1969-02-12 Whitefin Holding Sa Pyrrole derivatives
GB1154744A (en) 1966-05-17 1969-06-11 Whitefin Holding Sa Disubstituted Aminoethanols
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
CZ20002669A3 (cs) 1998-01-23 2001-11-14 National Jewish Medical And Research Center Pouľití proteinů tepelného ąoku nebo molekuly nukleové kyseliny, která jej kóduje, přípravek tyto látky obsahující, způsob výběru léčby přecitlivělosti nebo nedostatečnosti průchodu dýchacích cest
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
US20060148767A1 (en) 2001-12-06 2006-07-06 George Cioca Use of acyl salicylates as heat shock inducers
US20050137223A1 (en) 2003-11-12 2005-06-23 Amicus Therapeutics, Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
EP3441090A1 (en) 2005-05-17 2019-02-13 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CA2611011C (en) 2005-06-08 2014-01-28 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
WO2007098229A2 (en) 2006-02-21 2007-08-30 Michigan State University Geldanamycin derivatives and method of use thereof
US20070259820A1 (en) 2006-05-03 2007-11-08 The Regents Of The University Of Michigan Methods and reagents for activating heat shock protein 70
ES2709445T3 (es) 2006-05-16 2019-04-16 Amicus Therapeutics Inc Opciones de tratamiento para la enfermedad de Fabry
WO2007140212A2 (en) 2006-05-24 2007-12-06 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
KR101402554B1 (ko) 2006-06-23 2014-06-19 아미쿠스 세라퓨틱스, 인코포레이티드 β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
US20130045992A1 (en) * 2010-01-28 2013-02-21 President And Fellows Of Harvard College Compositions and Methods for Enhancing Proteasome Activity
CA2835610C (en) * 2011-05-12 2017-03-14 Proteostasis Therapeutics, Inc. Proteostasis regulators
US9849135B2 (en) * 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US9504680B2 (en) 2013-06-17 2016-11-29 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Also Published As

Publication number Publication date
CA3103954A1 (en) 2020-01-02
US11560385B2 (en) 2023-01-24
WO2020006296A1 (en) 2020-01-02
KR20210024588A (ko) 2021-03-05
PE20211804A1 (es) 2021-09-14
US20210115057A1 (en) 2021-04-22
BR122023023216A2 (pt) 2024-02-20
BR112020026580A2 (pt) 2021-03-23
EP3814338A1 (en) 2021-05-05
CN112585132A (zh) 2021-03-30
SG11202013026WA (en) 2021-01-28
IL279698A (en) 2021-03-01
JP2021529792A (ja) 2021-11-04
MX2020014082A (es) 2021-04-13
US20230183256A1 (en) 2023-06-15
MA53014A (fr) 2021-05-05
CL2020003380A1 (es) 2021-05-14
AU2019295765A1 (en) 2021-01-21
PH12020552261A1 (en) 2021-08-02

Similar Documents

Publication Publication Date Title
CR20200652A (es) Compuestos que aumentan la actividad del proteosoma
GEP20237506B (en) Pcsk9 antagonist compounds
MX2019003254A (es) Compuestos y metodos para la modulacion de ido y tdo, e indicaciones de estos.
GEP20227428B (en) Heterocyclic compounds as immunomodulators
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
MY186133A (en) Tgf-? inhibitors
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MY152271A (en) Novel compounds that are erk inhibitors
MX2016011992A (es) Derivados de piperidina-diona.
MA39956A (fr) Analogues du benzomorphane et leur utilisation
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2018004664A (es) Antagonistas de ep4.
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
EA202193015A1 (ru) Ингибиторы cdk
EP4001273A3 (en) Aminopyrimidines as alk inhibitors
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
WO2018039077A8 (en) Therapeutic compounds
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
CR20220029A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
SG11201810725WA (en) Novel β-lactamase inhibitors
MX2021005944A (es) Inhibidores de rip1.